CONMED
CNMD · Health Care Equipment
$49.25
0.4%Integra Lifesciences
IART · Health Care Equipment
$11.91
3.4%The short version
- Integra Lifesciences is the larger business, with $1.6B of revenue in fiscal 2025 against $1.4B for CONMED.
- CONMED grew revenue faster (5.2%, against 1.5%).
- CONMED kept more of each dollar of sales as operating profit (7.5% operating margin, against −30.2% operating margin).
- CONMED turned more of its sales into free cash flow (11.0% FCF margin, against −1.9% FCF margin).
- CONMED earned a higher return on the capital invested in it (3.7%, against −22.0%).
| Latest fiscal year | CNMD · FY25 | IART · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.5B | $936M |
| Revenue | $1.4B | $1.6B |
| Free cash flow | $151M | −$31.1M |
| Net income | $47.1M | −$517M |
| Growth | ||
| Revenue growth | 5.2% | 1.5% |
| 5-year growth | 9.8% | 3.6% |
| Share count change | 0.0% | −0.4% |
| Profitability | ||
| Gross margin | 54.6% | 50.9% |
| Operating margin | 7.5% | −30.2% |
| Net margin | 3.4% | −31.6% |
| FCF margin | 11.0% | −1.9% |
| Return on capital | 3.7% | −22.0% |
| Return on equity | 4.7% | −39.9% |
| Balance sheet | ||
| Net debt | $794M | $463M |
| Net debt / EBITDA | 5.1x | — |
| Dividends and buybacks | $24.7M | $0.2M |
| Valuation & quality | ||
| P/E | — | 70.1x |
| Piotroski F-score | 6 | 5 |
FY16
CNMD $764M
IART $992M
FY17
CNMD $796M
IART $1.2B
FY18
CNMD $860M
IART $1.5B
FY19
CNMD $955M
IART $1.5B
FY20
CNMD $863M
IART $1.4B
FY21
CNMD $1.0B
IART $1.5B
FY22
CNMD $1.0B
IART $1.6B
FY23
CNMD $1.2B
IART $1.5B
FY24
CNMD $1.3B
IART $1.6B
FY25
CNMD $1.4B
IART $1.6B
CNMD
IART
FY16
CNMD 4.9%
IART 11.6%
FY17
CNMD 5.9%
IART 3.8%
FY18
CNMD 8.3%
IART 7.5%
FY19
CNMD 8.3%
IART 6.2%
FY20
CNMD 5.3%
IART 11.0%
FY21
CNMD 10.9%
IART 12.8%
FY22
CNMD 6.7%
IART 15.3%
FY23
CNMD 9.7%
IART 7.2%
FY24
CNMD 15.3%
IART 1.8%
FY25
CNMD 7.5%
IART −30.2%
CNMD
IART
FY16
CNMD $25.1M
IART $69.1M
FY17
CNMD $52.7M
IART $71.0M
FY18
CNMD $58.2M
IART $122M
FY19
CNMD $75.1M
IART $162M
FY20
CNMD $51.5M
IART $165M
FY21
CNMD $96.9M
IART $264M
FY22
CNMD $11.6M
IART $222M
FY23
CNMD $106M
IART $73.1M
FY24
CNMD $154M
IART $25.0M
FY25
CNMD $151M
IART −$31.1M
CNMD
IART
FY16
CNMD 3.1%
IART 11.5%
FY17
CNMD 4.4%
IART 5.9%
FY18
CNMD 5.3%
IART 7.6%
FY19
CNMD 5.7%
IART 3.7%
FY20
CNMD 3.2%
IART 7.5%
FY21
CNMD 6.5%
IART 7.9%
FY22
CNMD 3.4%
IART 9.8%
FY23
CNMD 5.4%
IART 4.5%
FY24
CNMD 9.0%
IART 1.1%
FY25
CNMD 3.7%
IART −22.0%
CNMD
IART
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.